Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-09-26

Clinical Trial Update: A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing a single IV dose of TAK-925 in participants with idiopathic hypersomnia has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TAK-925

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Idiopathic Hypersomnia | Phase 1 | Status: COMPLETED | Results posted: 2023-09-26